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Biallelic MLH1 SNP cDNA expression or
constitutional promoter methylation can hide genomic
rearrangements causing Lynch syndrome
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Brigitte Royer-Pokora,5 Karsten Schulmann,6 Matthias Kloor,7 Wilhelm Höchter,8
Josef Weingart,8 Cortina Keiling,2 Trisari Massdorf,1 Elke Holinski-Feder,1,2 the
German HNPCC consortium
ABSTRACT
Background A positive family history, germline
mutations in DNA mismatch repair genes, tumours with
high microsatellite instability, and loss of mismatch repair
protein expression are the hallmarks of hereditary
non-polyposis colorectal cancer (Lynch syndrome).
However, in w10e15% of cases of suspected Lynch
syndrome, no disease-causing mechanism can be
detected.
Methods Oligo array analysis was performed to search
for genomic imbalances in patients with suspected
mutation-negative Lynch syndrome with MLH1
deficiency in their colorectal tumours.
Results and conclusion A deletion in the LRRFIP2
(leucine-rich repeat flightless-interacting protein 2) gene
flanking the MLH1 gene was detected, which turned out
to be a paracentric inversion on chromosome 3p22.2
creating two new stable fusion transcripts between
MLH1 and LRRFIP2. A single-nucleotide polymorphism in
MLH1 exon 8 was expressed from both alleles, initially
pointing to appropriate MLH1 function at least in
peripheral cells. In a second case, an inherited
duplication of the MLH1 gene region resulted in
constitutional MLH1 promoter methylation. Constitutional
MLH1 promoter methylation may therefore in rare cases
be a heritable disease mechanism and should not be
overlooked in seemingly sporadic patients.
INTRODUCTION
Hereditary non-polyposis colorectal cancer
(HNPCC) is the most common autosomal domi-
nant predisposition to early-onset colorectal cancer
(CRC) and increased risk of associated tumours in
endometrium, stomach, small intestine, hepato-
biliary system, ureter, renal pelvis, ovary, brain and
skin1 (MIM 114500). The molecular diagnosis of
HNPCC, also known as Lynch syndrome, is the
detection of a pathogenic germline mutation in one
of the DNA mismatch repair (MMR) genes MLH1
and MSH2, more rarely in MSH6, and to a lesser
extent in PMS2. Suspicion of HNPCC is raised
according to the Amsterdam criteria2 3 or the less
stringent Bethesda guidelines.4 Depending on the
HNPCC selection criteria, up to 70e80% of cases
can be solved and categorised as Lynch syndrome
due to pathogenic mutations, 15% carry unclassi-
fied sequence variants such as missense mutations
with unknown pathogenicity, but, in 10e15% of
cases of suspected Lynch syndrome, no disease-
causing mechanism can be detected. Therefore
further pathomechanisms are assumed to exist for
these genes (for a review, see Cooper et al5).
Deletions and duplications affecting exonic
regions in one of the MMR genes, whichdexcept
for partial exon deletions/duplicationsdare easy to
detect by multiplex ligation-dependent probe
amplification (MLPA), have been commonly found
in MSH2 and MLH16e15 and rarely in MSH6.16
Genomic rearrangements, such as deletions and
insertions within intronic regions or flanking the
gene in question, are difficult to both detectdfor
example, by Southern blot analysis9 11 13 17 or
custom-made zoom-in arrays18 19dand interpret.
So far, only one inversion involving MSH2 exon
1e7 is known to be a disease-causing mechanism in
Lynch syndrome.20 21 For MSH2, a transcriptional
silencing mechanism is induced by deletion of the
last exon of the EPCAM/TACSTD1 gene located
upstream of MSH2, leaving the MSH2 gene and
promoter intact.17 22 23 If at least EPCAM exon 9,
including the termination signal and poly-
adenylation site and the 39-UTR, is deleted, a fusion
transcript between EPCAM andMSH2 is generated.
Depending on EPCAM expression, this read-through
transcript into MSH2 silences normal MSH2 tran-
scription starting from exon 1 and induces MSH2
promoter methylationdfor example, in colon
mucosa. Such regulatory expression mechanisms
may also exist for MLH1, MSH6 and PMS2. Regu-
latory disturbances, such as antisense transcripts,
micro-RNAs, cis- and trans-regulatory elements,
upstream open reading frames and copy number
variations, are also possible causes of HNPCC
predisposition.5
Searching for additional hereditary disease-
causing mechanisms in MLH1, we analysed 32
cases of mutation-negative suspected Lynch
syndrome with MSI-H and MLH1 negative
tumours by comparative genomic hybridisation
(CGH) analysis and/or MLPA.
We here report for the first time a paracentric
inversion on chromosome 3p22.2 between the
DNA MMR gene, MLH1, and the downstream
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which creates two new stable fusion transcripts, thereby abol-
ishing MLH1 gene and protein function. Furthermore, we report
heritable partial MLH1 promoter methylation, which is induced
by a large genomic duplication including the complete MLH1
gene, the promoter and neighbouring genes.
MATERIALS AND METHODS
Patients
Twenty-three Amsterdam and nine Bethesda positive patients
with CRC negative for MLH1 immunohistochemistry were
included if MMR gene sequencing and deletion/duplication
screening did not detect any germline mutation. The BRAF
mutation p.Val600Glu was excluded in tumours of all nine
Bethesda patients. Ten patients from Amsterdam families with
MLH1 missense mutation of unclear pathogenicity were also
included. We also analysed one patient with a known duplica-
tion of the whole MLH1 gene region. Patients were recruited in
six centres of the German HNPCC consortium. All patients gave
written informed consent for the study, approved by the ethics
committees. DNA from peripheral blood cells was extracted
using the Flexigene Kit (Qiagen, Hilden, Germany), and DNA
extraction of tumour tissue and normal tissue from paraffin-
embedded material was achieved by microdissection.
Genomic situation
The genomic situation was analysed by oligo array CGH (oligo
aCGH; 105K; Agilent, Böblingen, Germany) and MLPA kits
(P008, P003, P248, ME011). MLPA analyses were performed
following the manufacturer ’s instructions. The methylation-
specific multiplex ligation-dependent probe amplification
(MS-MLPA kit ME011, MRC-Holland, Amsterdam, The
Netherlands) method quantifies the copy number and methyl-
ation in five CpG dinucleotides of the MLH1 promoter in DNA
from blood or tumour. In MS-MLPA, ligation of MLPA probes is
combined with digestion of genomic DNA with the methyla-
tion-sensitive endonuclease HhaI and calculated against the
undigested MLPA assay.
Abnormalities such as expected genomic breakpoints were
investigated by PCR with Expand Long-Range (Roche, Penzberg,
Germany) in a touch-down PCR programme over 64e508C
allowing amplification of fragments of 2e8 kb, which were then
sequenced.
cDNA analysis
Total RNAwas extracted from peripheral blood for all patients of
the study cohort using the PAXGene Blood RNA and Preparation
Kit (PreAnalytiX, Hombrechtikon, Switzerland). RNA isolation
after incubationwith andwithout emitine in cell culture to block/
not block nonsense-mediated mRNA decay (NMD) was carried
out only for the index patient of the family harbouring the
inversion. cDNA was generated with the First-strand cDNA-
Synthesis Kit (Amersham Biosciences, Freiburg, Germany).
Heterozygosity analysis of single-nucleotide polymorphism
(SNP) rs1799977 (c.655A/G; p.Ile219Val) in exon 8 ofMLH1was
performed with different primers in a standard procedure using
Ampli-Taq Gold (ABI, Munich, Germany) or LongAmp DNA
polymerase (NEB, Ipswich, UK) followed by sequencing.
For amplification of fusion transcripts, primers in LRRFIP2
exon 1 or 3 forward and MLH1 exon 19 reverse and MLH1 exon
13 forward and LRRFIP2 exon 29 reverse were used. Primer
sequences used to analyse potential fusion transcripts with other




Genomic situation at a first glance
Of the 31 patients with unexplained loss of MLH1 expression in
the CRC, oligo array analyses were performed in 17 patients
detecting a deletion in LRRFIP2, a gene located downstream of
MLH1 with antisense orientation (figure 1) in one case. The
deletion in the region downstream of MLH1 was verified by an
MLPA probe in LRRFIP2 exon 26, whereas MLH1 exon 1e19 and
its 39-UTR 128 nucleotides after the termination codon were
unaffected.
A deletion starting downstream of the MLH1 termination
codon affecting LRRFIP2 could itself not explain the pathoge-
nicity of the MLH1 gene.
cDNA analysis
To further clarify this finding, mRNA expression analyses were
performed for the patient using a heterozygous coding SNP
c.655A/G; p.Ile219Val in MLH1 exon 8. In cDNA isolated from
the PAX gene, the SNP in MLH1 showed biallelic expression by
amplifying exons 3e9, 6e9, 3e11, 7/8e14, but monoallelic
expression of the c.655G allele in PCR fragments from exon
1e19, 7/8e16, and 7/8e18. The cDNAwith emitine incubation
before RNA isolation to block NMD showed the same results
with monoallelic expression of the c.655G allele of MLH1 in
Long-Range PCR from exon 1e19. Biallelic expression seemed to
be restricted to mRNA fragments harbouring MLH1 exon 1e14,
and seemed to be monoallelic in full-length MLH1 transcripts.
Combining the genomic deletion in LRRFIP2 and the mono-
allelic MLH1 expression in cDNA analysis beyond exon 14, we
Figure 1 Schematic genomic organisation of MLH1 and LRRFIP2. The deletion detected by multiplex ligation-dependent probe amplification (MLPA)
probes and oligo array probes are depicted as arrows (in black for normal; in grey for 50% reduced signal intensity). Maximal and minimal deletion
estimates are shown in grey boxes. Transcription directions of the genes are indicated by arrows within the line constituting the genomic region of the
genes; exons are depicted as vertical bars.
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suspected a paracentric inversion with one breakpoint in the
genomic region of MLH1 and the other breakpoint downstream
of MLH1, possibly in the deleted region of LRRFIP2. Further
cDNA analyses identified two fusion transcripts, one of MLH1
exon 1e15 fused to LRRFIP2 exon 29 in-frame, and the other
one of LRRFIP2 exon 1e3 fused with MLH1 exon 16e19, also
in-frame (figure 2).
Genomic situation at a second glance
The inversion breakpoints in MLH1 intron 15 and LRRFIP2
intron 3 with deletion of 93.751 bp in LRRFIP2 comprising exons
4e28 were characterised in genomic DNA by Long-Range PCR
and sequencing (figure 3A). The breakpoint in MLH1 is located
after exon 15 in intron 15 c.1731+2148 and is fused to LRRFIP2
c.2056-221 within intron 28 of LRRFIP2, so thatMLH1 exon 1 to
exon 15 is now in line with LRRFIP2 exon 29 (last exon). The
remaining 39 sequence of MLH1 from intron 15 c.1731+2156
towards the 39-ends within the inverted fragment fused to
LRRFIP2 exon 1 to exon 3 c.90+1096 with sequence loss of seven
nucleotides, c.1731+2149_2155TACTTGA, in intron 15 and an
insertion of five nucleotides, ATGGT, between the breakpoints,
so that the genomic sequence of LRRFIP2 exon 1 to exon 3 is
now in line with MLH1 exon 16 to exon 19 (figure 3B). The
breakpoint within MLH1 intron 15 is localised within an AluSz
sequence motif; the sequence of the breakpoint in LRRFIP2
cannot be predicted because of the large deletion of 93 751 bp of
the genomic sequence of LRRFIP2 from intron 3 c.90+1097 to
intron 28 c.2056-222. A micro-homology of the sequence of
CAGGT was shared between MLH1 intron 15 and LRRFIP2
intron 28 at the fusion point.
Clinical data and further screening
The inversion was detected in the index CRC patient of a large
family (figure 4) fulfilling the Amsterdam criteria and segregated
with CRC and/or endometrial cancer, with ages of first tumour
diagnosis ranging from 26 to 52years in a further three family
members. Strikingly, one female without the inversion was
diagnosed as having ovarian cancer at the age of 47years, which is
not one of the major tumours in the HNPCC spectrum, espe-
cially not in MLH1 carriers, and a sigmoid colon cancer at the age
of 56years. As the inversion segregates with the other affected
family members, the tumours in this patient without MLH1
inversion were judged to be coincidental sporadic tumours.
We screened 12 cDNA samples from patients with suspected
Lynch syndrome with unclear MLH1 deficiency for fusion
transcripts of MLH1 and LRRFIP2 in one setting with primers
for MLH1 exon 1 forward and/or MLH1 exon 11 forward in
combination with primers for LRRFIP2 exon 29 reverse. In
a second setting, primers for LRRFIP2 exon 2 forward and MLH1
exon 19 reverse were used. These Long-Range PCR settings
allow amplification of different fusion transcripts between the
two genes up to 1.5 kb in size. Aside from the fragment ampli-
fied in the patient with the known inversion, no other fusion
transcripts were detected in other patients or controls. Of note,
as NMD destabilises transcripts harbouring a premature stop
codon at least before 55 nucleotides before the last
exonejunction complex, novel stable transcripts are expected
only in the case of in-frame fusion transcripts. Patients with out-
of-frame fusion transcripts between these two genes would
probably have been missed by this approach, as we had only
PAX RNA without a block of NMD for these patients.
Case 2
A large duplication of the complete MLH1 gene from exon 1 to
exon 19 including the promoter region was found in another
patient with CRC by MLPA, leaving the gene itself intact. CGH
analysis showed that the duplication started 59 of the TRANK1
(LBA1) gene completely encompassing EPM2AIP1, MLH1 and
LRRFIP2, and the 59 part of GOLGA4 (figure 5). The duplication
(minimal size 280 kb, maximal size 375 kb) is located intra-
chromosomally (3p22.2), as shown by fluorescence in situ
hybridisation with three probes covering the genomic region of
MLH1 (as published previously24). The MLH1 duplication was
identified in the index patient presenting with colon trans-
versum cancer at 39 years of age. His mother was sent for
colonoscopy after molecular testing revealed a carrier status,
where she was diagnosed as having CRC at the age of 65. His
sister was unaffected at the age of 44 years, and her twin brother
did not carry the duplication (figure 6).
All duplication carriers revealed an MLH1 promoter hyper-
methylation of five MLH1 probes of the MS-MLPA kit from 8%
to 18% or 14% to 25% in DNA from blood (figure 7), hair follicle,
colonic and buccal mucosa. As no coding SNP in MLH1 or
EPM2AIP1 was identified, quantification of MLH1 expression
could not be investigated in cDNA. Furthermore, no fusion
transcripts between TRANK1, EPM2AIP1, MLH1, LRRFIP2 and
GOLGA4 were detectable by PCR approaches using primers in
the above mentioned neighbouring genes and MLH1. However,
no cDNA with blocked NMD is available so far.
DISCUSSION
We report a disease-causing rearrangement mechanism, which at
first glance appeared to be a deletion of the LRRFIP2 gene
downstream of MLH1, but was revealed to be a paracentric
inversion between the two genes with one breakpoint in MLH1
intron 15 and the other breakpoint in LRRFIP2 intron 3, creating
two new in-frame fusion transcripts between these two genes
(figure 3A).
The inversion was found in an Amsterdam criteria positive
family, in four affected family members whose CRC was MSI-H
and negative for MLH1/PMS2 staining. After negative mutation
analysis of MLH1 and PMS2, expression analysis by testing
Figure 2 Sequences of fusion transcripts between MLH1 and LRRFIP2
in cDNA analyses. MLH1 exon 1e15 and LRRFIP2 exon 29 (top) and
LRRFIP2 exon 1e3 and MLH1 exon 16e19 (bottom). In-frame fusion
points are depicted by vertical lines within the sequences.
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Figure 3 (A) Genomic structure of the paracentric inversion. Top line: original genomic structure of MLH1 and LRRFIP2; exons are depicted in arrows
according to their transcriptional orientation, UTRs in boxes, MLH1 in dark grey and LRRFIP2 in unfilled (white) boxes and arrows. Second line: the
deleted region is represented by a box, filled in light grey. Third line: genomic structure after inversion with breakpoints in MLH1 intron 15 and LRRFIP2
intron 3 and deletion of LRRFIP2 exons 4e28. Bottom line: the stable fusion transcripts of MLH1 exon 1e15 and LRRFIP2 exon 29 and in antisense
direction LRRFIP2 exon 1e3 and MLH1 exon 16e19 both in-frame. (B) Sequence analysis of the genomic fusion points of the inversion in MLH1 intron
15 and LRRFIP2 intron 28 (top) and LRRFIP2 intron 3 and MLH1 intron 15 (bottom). In MLH1 intron 15, seven nucleotides were lost (red), and five
nucleotides (highlighted) were inserted within the fusion points of LRRFIP2 intron 3 andMLH1 intron 15; in LRRFIP2, intron 3 to intron 28 were deleted.
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small cDNA fragments including a SNP in MLH1 exon 8 also
produced normal results, indicating that we had not missed
a truncating mutation or a severe regulatory defect. aCGH
revealed a deletion in the flanking gene, LRRFIP2, pointing to
a possible genomic rearrangement. Only very detailed cDNA
analysis deciphered monoallelic expression of the 39 part of the
MLH1 transcript and fusion transcripts with the flanking
LRRFIP2 as the disease-causing mechanism. The inversion is
therefore assumed to be predisposing for Lynch syndrome.
It is now well established that repetitive DNA sequences, such
as Alu repeats, can act as facilitators of chromosomal rear-
rangements,25 as seems to be the case for the breakpoint in
MLH1 intron 15 located in an AluSz. The presence of a micro-
homology sequence of 5 nucleotides at the breakpoint junction
MLH1 intron 15 c.1731+2144_2148 and LRRFIP2 intron 28
c.2056-222_226 may indicate a homology-based joining
mechanism. As LRRFIP2 has a large deletion of 93.7 kb including
several Alu repeats, the original breakpoint potentially involving
an Alu repeat cannot be characterised.
We assume that the fusion of MLH1 exon 1e15 with LRRFIP2
exon 29, and LRRFIP2 exon 1e3 with MLH1 exon 16e19 would
abolish the protein function of both proteins. The leucine-rich
repeat flightless-interacting protein 2 encoded by LRRFIP2 is
ubiquitously expressed in all tissues, with higher expression in
heart and skeletal muscle. It may function as an activator of the
Wnt signalling pathway, in association with DVL3, upstream of
CTNNB1/b- catenin.26e29 So far, no mutations in LRRFIP2 have
been described in association with human disease. Besides CRC
predisposition (Lynch syndrome) caused by the defective MLH1
gene, no other disease phenotype was obvious in the affected
family described here that would have been attributable to
LRRFIP2 haploinsufficiency. No further in-frame fusion tran-
scripts between the two genes were detected by analysing
cDNAs of 12 patients with suspected Lynch syndrome with
unclear MLH1 deficiency. Out-of-frame fusion transcripts would
have been missed, as no NMD-blocked cDNA was available for
these patients. So far, only one disease-causing rearrangement
resulting in a fusion transcript ofMLH1 exons 1e11 with ITGA9
exons 17e28 in-frame has been described, which was generated
by an interstitial deletion of about 400 kb on chromosome
3p21.3 in a Lynch syndrome family.30
Partial duplications of MLH1 or MSH2 have been
described,6 13 14 19 31 but they never affected the complete
genomic region. We describe here a large duplication involving
the complete MLH1 gene, the promoter region and flanking
genes, leaving the gene itself intact. It was initially found in
a seemingly sporadic patient, but was also present in his affected
mother (diagnosed after surveillance colonoscopy was recom-
mended) and unaffected sister. All duplication carriers had a low
constitutional MLH1 promoter hypermethylation of 10e15%
detectable in different tissues. Hypermethylation in these
patients was assumed to be due to the duplication of MLH1 and
its flanking region, induced by a so far unknown mechanism.
Isolated deletion of MLH1 exon 1 and 2 resulted in one case in
constitutional promoter methylation and transcriptional
silencing of the gene.32 Promoter hypermethylation of MLH1
therefore seems to be a rare event in cases of heritable genomic
rearrangements of the MLH1 gene.
What lessons need to be learnt? Testing on biallelic SNP
expression in peripheral cells has been proposed as a large-scale
screening method and is a widely used tool to further clarify the
situation in patients without detectable germline mutation in
the supposedly affected gene.33 However, generation of fusion
transcripts can mimic normal biallelic expression and
hide genomic rearrangements or imbalances. Thorough cDNA
analysis therefore needs to cover the complete transcript in one
or several cDNA fragments of different size to ensure that
pathogenic ‘partial’ expression of the gene is not overlooked.
Analysis of the MLH1 promoter methylation in seemingly
sporadic patients (case 2) is usually, in combination with BRAF
Figure 4 Family pedigree of case 1
with (INV+) and without (INV) the
MLH1 inversion carriers and their ages
at tumour diagnosis in years. asc, colon
ascendens; biallic, biallelic; ca, cancer;
CRC, colorectal cancer; expr,
expression; IHC, immunohistochemical
staining; monoallic, monoallelic; P8,
MLH1 exon 8 single-nucleotide
polymorphism.
Figure 5 Schematic genomic
organisation of the duplication region
including the EPM2AIP1, MLH1 and
LRRFIP2 gene and part of GOLGA4
detected by multiplex ligation-
dependent probe amplification (MRC)
probes and oligo array probes depicted
as arrows (in black for normal; in grey
for duplicated signal intensity). The
minimal duplication is shown as a red
bar. Transcription directions of the
genes are indicated by arrows within
the line constituting the genomic region
of the genes, and exons are depicted as vertical bars.
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mutation analysis, restricted to DNA samples from the tumour
to sort out sporadic cases. To a far lesser extent, methylation of
the MLH1 promoter was found to be positive in the tumour and
in peripheral cells, again in sporadic patients.32 34e38 As long as
the mechanistic background remains unclear, aberrant MLH1
promoter methylation can be assumed to be the disease-causing
mechanism (in the sense of a de novo constitutional epimuta-
tion) and considered not to be inherited by the next generation
because of reprogramming in the germline. However, in the
literature, one case of maternal transmission of the constitu-
tional MLH1 epimutation to one son with 42% methylation in
blood and 0% methylation in sperm has been described, while
the other two allele-sharing sons were methylation negative.37
Promoter methylation can also be regarded as an indicator of
MLH1 silencing by other causes in cis (elements on DNA are
elements in the vicinity of the gene in question, trans elements
can be on another chromosome), which may be heritable,
especially if found at low methylation levels. In the present case,
a low degree of methylation was present in peripheral blood cells
and was probably due to a large genomic rearrangement.
A positive family history was revealed after genetic testing and
surveillance colonoscopy. Another example is mosaic MSH2
promoter methylation, as a result of expression-dependent
read-through of EPCAM transcription into MSH2, thereby
inducing transcriptional silencing of MSH2 in EPCAM-deletion
patients.22 23 Furthermore, a partial duplication of PTPRJ results
in silencing due to a read-through of duplicated exon 1e11 into
exon 2e3 of the intact gene causing promoter methylation.39
We do not yet routinely look for large genomic rearrangements
in these mostly sporadic patients withMLH1methylation in the
tumour without BRAF mutation to further clarify disease
mechanisms and define heritability. Large genomic rearrange-
ments other than exonic deletions or duplications are difficult to
detect, especially inversions without large deletions. In a previous
study, we ruled out translocations and large inversions by cyto-
genetic analysis (fluorescence in situ hybridisation) in 13 patients
with MLH1-negative tumours.24
The finding of abnormal resultsdthat is, duplications or
deletionsdin only a few probes of an oligo aCGH must be
verified with other methods and interpreted with caution.
Deletions and insertions flanking the gene in question or located
in intronic regions are not detected in routine diagnostics, and it
is difficult to judge their pathogenicity, as they may be rare and
not necessarily disease-causing, as demonstrated in the following
cases. A deletion far upstream of MLH1 was not regarded as
disease-causing, as it was reported in a patient also presenting
with deletion of MSH2 exon 1e7, as well as the deletion in
MSH2 intron 6, which was found in a patient with an additional
deletion in MLH1 exon 1.18 Three further aberrations were
reported: a deletion in MLH1 intron 13 and a deletion upstream
of MSH6 were of unclear pathogenicity, and an insertion in
PMS2 intron 7 proved to be pathogenic as it resulted in aberrant
splicing.17
Furthermore, regulatory disturbances, such as antisense tran-
scripts, micro-RNAs, cis- and trans-regulatory elements,
upstream open reading frames and copy number variations, are
also possible causes of HNPCC predisposition.5 In the remaining
unsolved cases of suspected HNPCC, we expect further patho-
mechanisms in the genome to decommission the respective gene,
which we hope will soon be detectable by new technologies such
as next generation sequencing.
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